Choreo LLC boosted its position in Coty Inc. (NYSE:COTY – Free Report) by 35.3% during the fourth quarter, Holdings ...

Mark Mahaney, Evercore ISI head of internet research, joins 'Closing Bell' to discuss the markets, Meta's historic winning ...

Evercore ISI has upgraded CRISPR (CRSP) to outperform from in line, citing upcoming data catalysts. Read more here.

Evercore ISI analyst Liisa Bayko raised the price target for CRISPR Therapeutics from $60.00 to $99.00. Bayko's optimism is driven by upcoming catalysts that could mark a new chapter for the company.

Evercore ISI analysts upgraded CRISPR Therapeutics stock from an In Line to an Outperform rating and increased the price target significantly to $99 from the previous $60. The upgrade comes as ...

Evercore ISI analyst Kirk Materne maintained a Hold rating on Tyler Technologies (TYL – Research Report) yesterday and set a price target of ...

Walgreens Chief Executive Officer Tim Wentworth reiterated on an earnings call last month that the company plans to divest ...

VillageMD, the health care clinic chain backed by Walgreens Boots Alliance Inc., is working with Evercore Inc. for assistance ...

In the lead-up to Nvidia Inc.’s NVDA forthcoming earnings report after market close on Feb.26, Evercore ISI suggests that it is a good buying opportunity amid strong fundamentals. What Happened: In a ...

Zurn Elkay has filed a registration statement (including a base prospectus) on Form S-3 and a preliminary prospectus supplement with the Securities and Exchange Commission (the “SEC”) for the offering ...

Rich Ross, head of technical analysis at Evercore ISI, said that a breakout to an all-time high in the S&P 500 ( SP500 ), ( ...

The "best" baseline scenario for the Fed in 2025 remains two cuts, taking into account a drag on growth from trade and restraint from higher long-term bond yields, Krishna Guha, vice chairman of ...